MHRA warns against Butterbur herbal remedies
26th January 2012
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has warned people not to take Butterbur (Petasites hybridus) herbal remedies due to the risk of hepatic toxicity. Products containing butterbur are being marketed in the UK, most commonly for the treatment of migraine and hayfever. However, none of these are licensed under the Traditional Herbal Registration Scheme.
Recent news
- Die zweite Ausgabe des APM Newsletter ist fertig.
- Prescribing and mixing controlled drugs - changes
- Tolvaptan: over-rapid increase in serum sodium and risk of serious neurological events
- Risks of hypomagnesaemia and increased risk of fracture with long-term PPI use
- NICE updated infection control guidelines
- MHRA alert for co-codamol 8/500 tablets
- NPSA RRR: Harm from flushing of nasogastric tubes before confirmation of placement
- Capsaicin patch license extension application withdrawn
- Wir freuen uns, Ihnen den ersten APM Newsletter vorstellen zu dürfen
- Alert update on Prednisolone e/c recalled from Teva
News archive
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000